206. Fragile X syndrome Clinical trials / Disease details
Clinical trials : 104 / Drugs : 87 - (DrugBank : 32) / Drug target genes : 54 - Drug target pathways : 79
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01517698 (ClinicalTrials.gov) | May 2012 | 20/1/2012 | A Study of RO4917523 in Patients With Fragile X Syndrome | A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome. | Fragile X Syndrome | Drug: Placebo;Drug: RO4917523 0.5 mg;Drug: RO4917523 1.5 mg | Hoffmann-La Roche | NULL | Completed | 14 Years | 50 Years | Both | 185 | Phase 2 | United States;Argentina;Canada;Chile;France;Mexico;Peru;Spain;Sweden;United Kingdom |